Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
Date:8/5/2008

ovel oral compound intended for the treatment of an undisclosed, common psychiatric disorder.

Updated 2008 Financial Guidance

Arena also reported that it updated its financial guidance for 2008 expenses for external clinical and preclinical study fees and expenses to approximately $130 to $138 million from $114 to $124 million. The change is primarily due to consolidating the lorcaserin pivotal trial program into two trials, BLOOM and BLOSSOM, while maintaining the same number of patients, approximately 7,000, originally planned across a three trial pivotal program. The entire Phase 3 program includes BLOOM, BLOSSOM and a non-pivotal Phase 3 trial, BLOOM-DM, which is expected to enroll approximately 600 patients. The increase is partially offset by reductions in expenses in the other development programs. Due to savings in other areas, including capital expenditures, as well as changes in the company's balance sheet, including an increase in accrued clinical expenses at the end of 2008 as compared to the beginning of 2008, Arena still expects to end 2008 with approximately $160 million in cash, cash equivalents and short-term investments, which assumes that common stock will be issued in connection with the conversion or redemption of outstanding shares of its series B redeemable convertible preferred stock, including any that may be redeemed on the series B-1's December 2008 mandatory redemption date. If Arena partners any of its programs, it would expect that its year-end cash, cash equivalents and short- term investments would be higher.

Scheduled Earnings Call

Arena will host both a conference call and webcast to discuss the second quarter 2008 financial results and to provide a corporate update today, Tuesday, August 5, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Jack Lief, President and Chief Executive Officer and Robert E. Hoffman, Vice President, Finance and Chief Financial Officer will host the conference call.


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
2. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
3. ThreeWire Expands Presence in the Pharmaceutical Arena
4. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
5. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... (PRWEB) January 23, 2015 Biofertilizers stimulate ... such as nitrogen and phosphorous through the activities in ... biofertilizers is increasing due to the stress on reducing ... fertilizers. , The report defines and segments the bio ...
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... Johnston, RI (PRWEB) January 22, 2015 ... State , The growing team of brand-neutral, independent consultants, ... CIO Philip Rogers explained that over the years, his ... including , Moroso, Town of Plainfield, as well as ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2
... SAN DIEGO, July 23 Anadys Pharmaceuticals, Inc. (Nasdaq: ... financial results on Thursday, July 30, 2009, after the U.S. financial markets ... conference call and webcast on Thursday, July 30, 2009 at 5:00 p.m. ... highlights and to provide an update on its development programs. A ...
... , , , , DALLAS, ... E S S PHARMACEUTICALS, INC. ... European partner, SpePharm , is collecting data from a post approval ... UK showing prevention of oral mucositis. In a multi-center study expected to enroll ...
... Calif., July 23 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) ... 2009 Growth Stock & National Sales Conference on Thursday, July 30, 2009 ... Florida. , , More information about the ... , About Peregrine Pharmaceuticals , ...
Cached Biology Technology:Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results 2MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 2MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 3
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
(Date:1/22/2015)... Jan. 22, 2015 Infinisource has launched its new NXG ... model. The G2 sets a higher standard for collecting attendance ... management solution. With plug-and-play installation, touch screen interface and seamless ... a robust time collection solution for the small to mid-size ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 Following ... the fingerprint reading feature with the iPhone 5S. It ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... with Primary Angle Closure Glaucoma (PACG), a leading cause ... people worldwide, 80% of whom live in Asia. ... Nature Genetics , on 26 August 2012, was ... Institute (SERI)/Singapore National Eye Centre (SNEC), Genome Institute of ...
... 2012 Researchers at the Hebrew University of Jerusalem ... the autonomic nervous system -- reaches the bones and ... The newly discovered pathway has a key role in ... the skeletal resistance to fracture throughout one,s entire life, ...
... Operon, one of the pioneers and key providers of ... 2500 and an Illumina MiSeq sequencer to its fleet ... will be able to provide customers with NGS services ... Whilst technological innovation has improved the general performance of ...
Cached Biology News:Singapore scientists find genes associated with glaucoma, a major cause of eye blindness 2Singapore scientists find genes associated with glaucoma, a major cause of eye blindness 3New neural pathway controlling skeletal development discovered 2New neural pathway controlling skeletal development discovered 3
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
...
... the first fully genetically encoded fluorescent sensor ... hydrogen peroxide (H2O2), one of the main ... basis of yellow fluorescent protein inserted into ... OxyR (OxyR-RD), HyPer demonstrates submicromolar affinity to ...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: